| Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
steroid 5 alpha-reductase 2 | 0.564 | 0.615 |
|
group | 0.400 | None | 1.000 | 26 | 0 | 2000 | 2015 | |||||||||
|
prostate cancer associated 3 | 0.663 | 0.615 |
|
group | 0.090 | None | 1.000 | 9 | 0 | 2002 | 2017 | |||||||||
|
prostate cancer associated transcript 4 | 0.839 | 0.192 |
|
group | 0.030 | None | 1.000 | 3 | 0 | 2001 | 2007 | |||||||||
|
microRNA 21 | 0.363 | 0.846 |
|
group | 0.330 | None | 1.000 | 3 | 0 | 2012 | 2019 | |||||||||
|
POU class 5 homeobox 1 pseudogene 3 | 0.452 | 0.808 |
|
group | 0.030 | None | 1.000 | 3 | 0 | 2009 | 2013 | |||||||||
|
POU class 5 homeobox 1 pseudogene 4 | 0.452 | 0.808 |
|
group | 0.030 | None | 1.000 | 3 | 0 | 2009 | 2013 | |||||||||
|
microRNA 888 | 0.760 | 0.192 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2014 | 2018 | |||||||||
|
CD24 molecule | 0.472 | 0.769 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2009 | 2016 | |||||||||
|
SWI/SNF complex antagonist associated with prostate cancer 1 | 0.751 | 0.192 |
|
group | 0.310 | None | 1.000 | 2 | 0 | 2013 | 2013 | |||||||||
|
H3 histone pseudogene 23 | 0.443 | 0.769 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2017 | 2018 | |||||||||
|
H3 histone pseudogene 10 | 0.350 | 0.846 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2000 | 2000 | |||||||||
|
cancer/testis antigen 1B | 0.507 | 0.731 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2003 | 2006 | |||||||||
|
Nanog homeobox retrogene P8 | 0.769 | 0.192 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2013 | 2014 | |||||||||
|
microRNA 182 | 0.486 | 0.846 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2013 | 2019 | |||||||||
|
microRNA 212 | 0.535 | 0.808 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2016 | 2017 | |||||||||
|
microRNA 375 | 0.476 | 0.769 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2012 | 2017 | |||||||||
|
microRNA 146b | 0.496 | 0.769 |
|
group | 0.020 | None | 1.000 | 2 | 0 | 2012 | 2016 | |||||||||
|
kallikrein pseudogene 1 | 0.839 | 0.154 |
|
group | 0.310 | None | 1.000 | 2 | 0 | 2006 | 2008 | |||||||||
|
microRNA 940 | 0.604 | 0.577 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2014 | 2014 | |||||||||
|
SOD2 overlapping transcript 1 | 0.722 | 0.500 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2003 | 2003 | |||||||||
|
microRNA 1301 | 0.711 | 0.269 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2017 | 2017 | |||||||||
|
microRNA 1908 | 0.670 | 0.577 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2017 | 2017 | |||||||||
|
PPT2-EGFL8 readthrough (NMD candidate) | 0.792 | 0.462 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2018 | 2018 | |||||||||
|
Spermatogenic failure | 0.792 | 0.115 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2016 | 2016 | |||||||||
|
prostate cancer associated transcript 1 | 0.575 | 0.615 |
|
group | 0.300 | None | 1.000 | 1 | 0 | 2016 | 2016 |